Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
45 participants
OBSERVATIONAL
2023-10-12
2031-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will:
* give one blood draw of 5 mL
* have one Dexa Scan taken to measure adipose and muscle mass
* have a camera placed under the tongue to take pictures of blood vessels
* have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion
Researchers will compare blood vessel function of those who take estrogen to those who do not.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Estrogen and Diabetes
NCT03436992
Estrogen Deficiency on Cardiovascular Risk
NCT06369363
Women's Angiographic Vitamin and Estrogen Trial (WAVE)
NCT00000555
Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women
NCT01633814
Vascular Effect of Estradiol Valerate Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery
NCT02161614
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Continuous estrogen/progestin
Females who have had continuous estrogen/progestin treatment for a minimum of 1 year.
Nω-nitro-L-arginine methyl ester (L-NAME)
L-NAME will be infused locally through microdialysis catheters.
Acetylcholine
ACh will be infused locally through microdialysis catheters.
Sodium Nitroprusside
SNP will be infused locally through microdialysis catheters.
No Estrogen/progestin
Females who have not had continuous estrogen treatment for a minimum of 5 years.
Nω-nitro-L-arginine methyl ester (L-NAME)
L-NAME will be infused locally through microdialysis catheters.
Acetylcholine
ACh will be infused locally through microdialysis catheters.
Sodium Nitroprusside
SNP will be infused locally through microdialysis catheters.
Continuous progestin
Females who have had continuous progestin treatment for a minimum of 1 year.
Nω-nitro-L-arginine methyl ester (L-NAME)
L-NAME will be infused locally through microdialysis catheters.
Acetylcholine
ACh will be infused locally through microdialysis catheters.
Sodium Nitroprusside
SNP will be infused locally through microdialysis catheters.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nω-nitro-L-arginine methyl ester (L-NAME)
L-NAME will be infused locally through microdialysis catheters.
Acetylcholine
ACh will be infused locally through microdialysis catheters.
Sodium Nitroprusside
SNP will be infused locally through microdialysis catheters.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults aged 18-40 years
* Females with estrogen/progestin treatment for a minimum of 1 year.
* Blood pressure \<140/ \< 90 mmHg
* No more than 1 cardiovascular risk factor Control Groups
* Adults aged 18-40 years
* Female with no estrogen/progestin treatment for minimum of 5 years.
* Female undergoing progestin only treatment for a minimum of 1 year.
* Blood pressure \<140/ \< 90 mmHg
* No more than 1 cardiovascular risk factor
Exclusion Criteria
* Rash, skin disease, or pigmentation disorders on both forearms
* Anemia
* Kidney Disease
* Known skin allergies
* Smoking or tobacco use within last 6 months
* Coronary Artery Disease
-1 cardiovascular risk factor Hypertension Diabetes Hypercholesterolemia Hyperlipidemia
* Bleeding disorders
* Use of anti-coagulants
* Allergies to study drugs
* Use of topical/non-topical steroids in last 6 months
* Internal mouth sores
* Forearms covered with tattoos
* Pregnancy
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical College of Wisconsin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Julie K. Freed
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Froedtert Hospital
Wauwatosa, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO40920
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.